Three multidistrict litigations involving the risks of transvaginal mesh were consolidated this past week into a single MDL before Chief Judge Joseph R. Goodwin the U.S. District Court for the Southern District of West Virginia. The MDLs were filed against Boston Scientific, American Medical Systems and Johnson & Johnson’s Ethicon Inc.
Judge Goodwin was already handling another MDL involving Avaulta transvaginal mesh against C.R. Bard. Consolidating so many similar MDLs before one judge is very unusual. However it will benefit our clients to have a streamlined process overseen by the same judge, regardless of which company manufactured their defective TVM implant.
Transvaginal surgical mesh is a medical device that is generally used to repair weakened or damaged tissue in urogynecology procedures, including repair of pelvic organ prolapsed and stress urinary incontinence.
Every year approximately 100,000 women diagnosed with pelvic organ prolapsed are treated with surgically implanted transvaginal mesh. In July, the FDA released a warning about TVM, saying not only do women have a high risk of complications associated with implanting transvaginal mesh, but that the surgery may not be more effective when compared to traditional non-mesh repair.
As a result, the FDA has required the above manufactures to conduct additional studies to investigate the serious complications now becoming associated with the use of transvaginal surgical mesh.